STOCK TITAN

Vanguard amends Schedule 13G/A — AMPH (Vanguard reports 0 shares)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Amphastar Pharmaceuticals Inc received an amended Schedule 13G/A from The Vanguard Group reporting that Vanguard beneficially owns 0 shares of Amphastar common stock as disclosed in the amendment dated 03/13/2026 and signed 03/26/2026.

The filing explains this zero ownership reflects an internal realignment at The Vanguard Group, Inc.; certain subsidiaries or business divisions now report beneficial ownership separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The amendment lists Vanguard's voting and dispositive powers as 0 and states Vanguard's aggregate ownership is 0% of the class.

Positive

  • None.

Negative

  • None.

Insights

Schedules show administrative disaggregation, not a market trade.

The amendment documents an internal reallocation of reporting responsibility within The Vanguard Group under SEC Release No. 34-39538. It records 0 shares beneficially owned and zero voting/dispositive power.

This is a reporting change driven by structure; cash‑flow treatment and trading activity are not described in the excerpt. Subsequent filings by Vanguard subsidiaries may show holdings separately.

Disaggregation clarifies which Vanguard entities report holdings.

The amendment states that certain Vanguard subsidiaries or business divisions will report beneficial ownership separately and that Vanguard no longer is deemed to beneficially own those securities. This is a compliance-driven reallocation of reporting responsibility rather than a change in economic ownership as described in the excerpt.

Review later filings from named subsidiaries for the redistributed holdings and any voting‑power disclosures tied to those entities.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026

FAQ

What does Vanguard report for AMPH in this Schedule 13G/A?

Vanguard reports 0 shares beneficially owned and 0% of Amphastar common stock. The filing lists zero sole and shared voting and dispositive powers for Vanguard.

Why does The Vanguard Group report zero ownership for AMPH?

The filing explains an internal realignment on January 12, 2026, causing certain Vanguard subsidiaries to report ownership separately under SEC Release No. 34-39538, which results in Vanguard reporting zero here.

Does the amendment indicate Vanguard sold AMPH shares?

No. The amendment attributes the change to reporting disaggregation under SEC guidance; it does not describe any sale, purchase, or cash consideration in the provided excerpt.

Who signed the Schedule 13G/A for Vanguard?

The filing is signed by Ashley Grim, Head of Global Fund Administration, with a signature date of 03/26/2026, attesting to the amended disclosure.

Will other Vanguard filings show the redistributed AMPH holdings?

The amendment states subsidiaries or business divisions will report beneficial ownership separately; related filings by those Vanguard entities may disclose the redistributed holdings after the realignment.
Amphastar Pharma

NASDAQ:AMPH

View AMPH Stock Overview

AMPH Rankings

AMPH Latest News

AMPH Latest SEC Filings

AMPH Stock Data

886.08M
33.95M
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
RANCHO CUCAMONGA